|
CA2603408C
(en)
|
2005-03-31 |
2018-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
ES2654040T3
(es)
|
2006-03-31 |
2018-02-12 |
Chugai Seiyaku Kabushiki Kaisha |
Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
|
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
|
MX336725B
(es)
|
2007-09-26 |
2016-01-28 |
Chugai Pharmaceutical Co Ltd |
Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
|
|
RU2526512C2
(ru)
|
2007-09-26 |
2014-08-20 |
Чугаи Сейяку Кабусики Кайся |
Модифицированная константная область антитела
|
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
CN105585630B
(zh)
|
2010-07-29 |
2020-09-15 |
Xencor公司 |
具有修改的等电点的抗体
|
|
EP3318633A1
(en)
|
2010-11-17 |
2018-05-09 |
Chugai Seiyaku Kabushiki Kaisha |
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
|
|
SG190726A1
(en)
|
2010-11-30 |
2013-07-31 |
Chugai Pharmaceutical Co Ltd |
Cytotoxicity-inducing therapeutic agent
|
|
BR112013023918A2
(pt)
*
|
2011-03-25 |
2016-12-13 |
Glenmark Pharmaceuticals Sa |
imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
CN104822704B
(zh)
*
|
2012-06-14 |
2020-02-14 |
医疗生物科学有限公司 |
针对分化簇3(cd3)的人源化的抗体
|
|
IN2015MN00139A
(enExample)
*
|
2012-09-25 |
2015-10-16 |
Glenmark Pharmaceuticals Sa |
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
KR102391731B1
(ko)
|
2013-01-14 |
2022-04-27 |
젠코어 인코포레이티드 |
신규한 이형이량체 단백질
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
EP2945969A1
(en)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
US10351626B2
(en)
|
2013-03-14 |
2019-07-16 |
The Scripps Research Institute |
Targeting agent antibody conjugates and uses thereof
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
DK2970486T3
(en)
|
2013-03-15 |
2018-08-06 |
Xencor Inc |
MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
|
|
WO2015046467A1
(ja)
|
2013-09-27 |
2015-04-02 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
CN105873953A
(zh)
*
|
2013-11-04 |
2016-08-17 |
格兰马克药品股份有限公司 |
重靶向t细胞的异源二聚免疫球蛋白的产生
|
|
JP6449295B2
(ja)
|
2013-12-17 |
2019-01-09 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体および使用方法
|
|
TN2017000532A1
(en)
*
|
2014-03-28 |
2019-04-12 |
Xencor Inc |
Bispecific antibodies that bind to cd38 and cd3.
|
|
WO2015156268A1
(ja)
|
2014-04-07 |
2015-10-15 |
中外製薬株式会社 |
免疫活性化抗原結合分子
|
|
CN106459954A
(zh)
|
2014-05-13 |
2017-02-22 |
中外制药株式会社 |
用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
|
|
AU2015314744A1
(en)
|
2014-09-12 |
2017-03-02 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
MA40894A
(fr)
*
|
2014-11-04 |
2017-09-12 |
Glenmark Pharmaceuticals Sa |
Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
CN107406512A
(zh)
*
|
2014-11-26 |
2017-11-28 |
Xencor公司 |
结合cd3和cd38的异二聚体抗体
|
|
BR112017011092A2
(pt)
|
2014-11-26 |
2017-12-26 |
Xencor Inc |
anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
|
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
SG11201706774WA
(en)
*
|
2015-02-27 |
2017-09-28 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
|
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
|
US11142587B2
(en)
|
2015-04-01 |
2021-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing polypeptide hetero-oligomer
|
|
GB201506868D0
(en)
*
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method for protein purification
|
|
CN115109158A
(zh)
|
2015-05-07 |
2022-09-27 |
阿吉纳斯公司 |
抗ox40抗体及其使用方法
|
|
PT3310814T
(pt)
|
2015-06-16 |
2023-10-02 |
H Hoffnabb La Roche Ag |
Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
|
|
TW201718647A
(zh)
|
2015-06-16 |
2017-06-01 |
建南德克公司 |
抗-cll-1抗體及使用方法
|
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック， インコーポレイテッド |
抗ｃｄ３抗体及び使用方法
|
|
MY180297A
(en)
|
2015-06-24 |
2020-11-27 |
Hoffmann La Roche |
Anti-transferrin receptor antibodies with tailored affinity
|
|
CA2990177A1
(en)
|
2015-06-25 |
2016-12-29 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars), compositions and methods thereof
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
MX2018003822A
(es)
|
2015-10-02 |
2018-06-22 |
Hoffmann La Roche |
Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
CN116675776A
(zh)
|
2015-10-25 |
2023-09-01 |
赛诺菲 |
用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
|
|
JP6925278B2
(ja)
*
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
|
US11660340B2
(en)
|
2015-11-18 |
2023-05-30 |
Chugai Seiyaku Kabushiki Kaisha |
Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
|
|
CA3007233A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
CN110698560B
(zh)
*
|
2015-12-24 |
2021-11-26 |
凯惠科技发展(上海)有限公司 |
一种tpbg抗体及其制备方法、其偶联物和应用
|
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
|
|
AU2017213886B2
(en)
|
2016-02-04 |
2024-03-07 |
The California Institute For Biomedical Research |
Humanized anti-CD3 antibodies, conjugates and uses thereof
|
|
EP3433273B1
(en)
|
2016-03-25 |
2021-12-29 |
Biomunex Pharmaceuticals |
Binding molecules to cd38 and pd-l1
|
|
CN109476732B
(zh)
|
2016-04-13 |
2024-03-22 |
赛诺菲 |
三特异性和/或三价结合蛋白
|
|
MY192090A
(en)
|
2016-04-13 |
2022-07-26 |
Sanofi Sa |
Trispecific and/or trivalent binding proteins
|
|
AU2017255970B2
(en)
|
2016-04-28 |
2024-06-27 |
Biomunex Pharmaceuticals |
Bispecific antibodies targeting EGFR and HER2
|
|
MA44780A
(fr)
|
2016-04-28 |
2019-03-06 |
Chugai Pharmaceutical Co Ltd |
Préparation contenant un anticorps
|
|
EP3468586B1
(en)
|
2016-06-14 |
2024-08-07 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
US11613572B2
(en)
|
2016-06-21 |
2023-03-28 |
Teneobio, Inc. |
CD3 binding antibodies
|
|
US20200283534A1
(en)
|
2016-06-24 |
2020-09-10 |
iCell Gene Therapeuticics LLC |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
WO2018005706A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
|
KR102435801B1
(ko)
*
|
2016-07-22 |
2022-08-25 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20240044520A
(ko)
|
2016-09-14 |
2024-04-04 |
테네오원, 인코포레이티드 |
Cd3 결합 항체
|
|
KR20190065318A
(ko)
|
2016-09-23 |
2019-06-11 |
메뤼스 엔.페. |
세포에 의해 발현되는 생물학적 활성을 조절하는 결합 분자
|
|
CN106632681B
(zh)
|
2016-10-11 |
2017-11-14 |
北京东方百泰生物科技有限公司 |
抗egfr和抗cd3双特异抗体及其应用
|
|
MX2019004327A
(es)
|
2016-10-14 |
2019-10-14 |
Xencor Inc |
Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
|
|
EP3538152A4
(en)
|
2016-11-09 |
2020-09-30 |
Agenus Inc. |
ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
|
|
WO2018093821A1
(en)
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4215548A1
(en)
|
2016-12-21 |
2023-07-26 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
CN106749678A
(zh)
*
|
2017-01-09 |
2017-05-31 |
北京普瑞金科技有限公司 |
Her2 car重组慢病毒载体及其构建方法与应用
|
|
SG11201908825TA
(en)
|
2017-03-27 |
2019-10-30 |
Biomunex Pharmaceuticals |
Stable multispecific antibodies
|
|
SG11201909498XA
(en)
*
|
2017-04-24 |
2019-11-28 |
Glenmark Pharmaceuticals Sa |
T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
|
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
|
WO2018224441A1
(en)
*
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-cd3 antibodies
|
|
JP7710827B2
(ja)
*
|
2017-06-05 |
2025-07-22 |
ヤンセン バイオテツク，インコーポレーテツド |
非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
|
|
KR102651965B1
(ko)
*
|
2017-06-05 |
2024-03-28 |
누맙 세러퓨틱스 아게 |
신규 항 cd3 항체
|
|
CN118146370A
(zh)
|
2017-06-20 |
2024-06-07 |
特纳奥尼股份有限公司 |
仅有重链的抗bcma抗体
|
|
CN117866097A
(zh)
|
2017-06-20 |
2024-04-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
CN111247242B
(zh)
|
2017-06-21 |
2024-07-19 |
美商生物细胞基因治疗有限公司 |
嵌合抗原受体(CARs)、组合物及其使用方法
|
|
EP3645122A1
(en)
|
2017-06-30 |
2020-05-06 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
|
|
WO2019034580A1
(en)
|
2017-08-14 |
2019-02-21 |
Morphosys Ag |
HUMANIZED ANTIBODIES FOR CD3
|
|
CA3075399A1
(en)
*
|
2017-09-13 |
2019-03-21 |
Teneobio, Inc. |
Heavy chain antibodies binding to ectoenzymes
|
|
JP7036909B2
(ja)
*
|
2017-10-10 |
2022-03-15 |
サノフイ |
抗ｃｄ３８抗体および使用方法
|
|
IL274265B1
(en)
|
2017-11-01 |
2025-09-01 |
Chugai Pharmaceutical Co Ltd |
Variant and isoform of an antibody with attenuated biological activity
|
|
WO2019094637A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
|
KR102782136B1
(ko)
|
2017-11-08 |
2025-03-18 |
쿄와 기린 가부시키가이샤 |
CD40과 EpCAM에 결합하는 이중특이적 항체
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
SG11202005732XA
(en)
|
2017-12-19 |
2020-07-29 |
Xencor Inc |
Engineered il-2 fc fusion proteins
|
|
WO2019133761A1
(en)
*
|
2017-12-27 |
2019-07-04 |
Teneobio, Inc. |
Cd3-delta/epsilon heterodimer specific antibodies
|
|
WO2019143636A1
(en)
*
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
|
MA51793A
(fr)
|
2018-02-08 |
2020-12-16 |
Hoffmann La Roche |
Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
|
|
CN120399075A
(zh)
*
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
CN110305217B
(zh)
|
2018-03-27 |
2022-03-29 |
广州爱思迈生物医药科技有限公司 |
双特异性抗体及其应用
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
|
WO2019204665A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
FI3797121T3
(fi)
*
|
2018-05-23 |
2024-08-22 |
Pfizer |
Cd3:lle spesifisiä vasta-aineita ja niiden käyttöjä
|
|
WO2019224385A2
(en)
*
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
|
WO2019244107A1
(en)
*
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
|
MX2021001915A
(es)
|
2018-08-17 |
2021-05-31 |
Regeneron Pharma |
Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
|
|
EP3620785A1
(en)
*
|
2018-09-07 |
2020-03-11 |
Ares Trading S.A. |
Electrophoresis-based characterization of fc fusion proteins
|
|
CA3113756A1
(en)
*
|
2018-09-25 |
2020-04-02 |
Ichnos Sciences S.A. |
Antibody quantification in biological samples
|
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
|
MX2021004147A
(es)
|
2018-10-09 |
2021-09-08 |
Sanofi Sa |
Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
|
|
US20210388106A1
(en)
*
|
2018-10-26 |
2021-12-16 |
Teneobio, Inc. |
Heavy chain antibodies binding to cd38
|
|
WO2020112970A1
(en)
*
|
2018-11-30 |
2020-06-04 |
The Trustees Of The University Of Pennsylvania |
Bw6 specific car designed to protect transplanted tissue from rejection
|
|
CN113260379B
(zh)
|
2018-12-21 |
2022-09-02 |
浙江时迈药业有限公司 |
蛋白酶可切割的双特异性抗体及其用途
|
|
SG11202109406TA
(en)
|
2019-03-01 |
2021-09-29 |
Xencor Inc |
Heterodimeric antibodies that bind enpp3 and cd3
|
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
|
CN114008079A
(zh)
*
|
2019-03-20 |
2022-02-01 |
贾夫林肿瘤学公司 |
抗adam12抗体和嵌合抗原受体以及包含其的组合物和方法
|
|
PE20220142A1
(es)
|
2019-04-05 |
2022-01-27 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
KR102239781B1
(ko)
|
2019-04-08 |
2021-04-13 |
주식회사 녹십자 |
Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
|
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
|
MX2021014193A
(es)
*
|
2019-05-23 |
2022-01-06 |
Velosbio Inc |
Moleculas de enlace biespecificas anti-ror1/anti-cd3.
|
|
EP3983438A1
(en)
|
2019-06-14 |
2022-04-20 |
TeneoBio, Inc. |
Multispecific heavy chain antibodies binding to cd22 and cd3
|
|
JP2022538008A
(ja)
*
|
2019-06-26 |
2022-08-31 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫エフェクター細胞をターゲット化して増殖させるための方法及び材料
|
|
CN110551221B
(zh)
*
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
EP3999115A4
(en)
*
|
2019-07-12 |
2023-11-22 |
LipUm AB |
NEW BSSL ANTIBODIES
|
|
EP3791931A1
(en)
*
|
2019-09-13 |
2021-03-17 |
Ichnos Sciences SA |
Bispecific antibodies for the treatment of solid tumors
|
|
US20220348661A1
(en)
|
2019-09-30 |
2022-11-03 |
Harbour Biomed (suzhou) Co., Ltd. |
Cd3-targeting antibody, bispecific antibody and use thereof
|
|
CN112876563B
(zh)
*
|
2019-11-29 |
2022-08-16 |
康诺亚生物医药科技（成都）有限公司 |
药物组合物及其制备方法和应用
|
|
MX2022006972A
(es)
*
|
2019-12-26 |
2022-08-04 |
Abl Bio Inc |
Metodo para la purificacion de peptido biologicamente activo utilizando cromatografia de afinidad con proteina a.
|
|
CA3165045A1
(en)
*
|
2020-01-23 |
2021-07-29 |
Adagene Ag |
Heterodimeric proteins with fc mutations
|
|
TWI888487B
(zh)
|
2020-02-14 |
2025-07-01 |
日商協和麒麟股份有限公司 |
與ｃｄ３結合之雙特異性抗體
|
|
EP4106880A4
(en)
*
|
2020-02-17 |
2024-07-03 |
Board of Regents, The University of Texas System |
HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
|
|
TWI874613B
(zh)
*
|
2020-03-17 |
2025-03-01 |
美商西雅圖免疫公司 |
微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
|
|
CA3218661A1
(en)
|
2020-04-04 |
2022-11-17 |
David Campbell |
Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
|
|
WO2021222595A2
(en)
*
|
2020-04-30 |
2021-11-04 |
Virtuoso Binco, Inc. |
Multispecific antibodies targeting cd38 and epcam and uses thereof
|
|
IL297412A
(en)
|
2020-05-04 |
2022-12-01 |
Immunorizon Ltd |
Precursor tri-specific antibody constructs and methods of use thereof
|
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
CN115996704A
(zh)
*
|
2020-06-12 |
2023-04-21 |
伊克诺斯科学公司 |
抗体制剂稀释剂
|
|
TWI806088B
(zh)
|
2020-06-30 |
2023-06-21 |
大陸商和鉑醫藥（上海）有限責任公司 |
具有H2L2與HCAb結構的結合蛋白
|
|
CN120040592A
(zh)
*
|
2020-07-31 |
2025-05-27 |
百奥泰生物制药股份有限公司 |
Cd47抗体及其应用
|
|
US11197910B1
(en)
|
2020-08-19 |
2021-12-14 |
Vitruviae LLC |
Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
|
|
EP4200332A1
(en)
|
2020-08-19 |
2023-06-28 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
|
US11124568B1
(en)
*
|
2020-08-19 |
2021-09-21 |
Vitruviae LLC |
CD3/CD25 antibodies for neuro-immune diseases
|
|
KR20230054456A
(ko)
|
2020-08-25 |
2023-04-24 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv를 표적으로 하는 다중특이적 항원 결합 분자 및 이의 사용 방법
|
|
US20230406955A1
(en)
*
|
2020-10-22 |
2023-12-21 |
Janux Therapeutics, Inc. |
Antibodies targeting her2 and cd3 and uses thereof
|
|
AU2021374592A1
(en)
|
2020-11-04 |
2023-06-01 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
EP4240766A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
|
|
WO2022148736A1
(en)
*
|
2021-01-05 |
2022-07-14 |
Transgene |
Vectorization of muc1 t cell engager
|
|
FI4284512T3
(fi)
|
2021-01-28 |
2025-05-22 |
Regeneron Pharma |
Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
|
|
EP4305067A1
(en)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
JP2024509274A
(ja)
|
2021-03-10 |
2024-02-29 |
ゼンコア インコーポレイテッド |
Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
|
|
MX2023011267A
(es)
|
2021-03-24 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
|
|
CN114763387B
(zh)
*
|
2021-04-15 |
2024-06-25 |
北京大学深圳研究生院 |
一种基于结构优化蛋白活性的三特异性抗体制备方法
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
JP2024530166A
(ja)
*
|
2021-08-04 |
2024-08-16 |
アブプロ コーポレーション |
Ｃｄ３標的化抗体及びそれらの使用
|
|
EP4405392A1
(en)
*
|
2021-09-24 |
2024-07-31 |
Janssen Biotech, Inc. |
Proteins comprising cd20 binding domains, and uses thereof
|
|
AU2023254191A1
(en)
|
2022-04-11 |
2024-10-17 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
JP2025519477A
(ja)
|
2022-06-07 |
2025-06-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔ細胞活性を調節するための多重特異性分子及びその使用
|
|
WO2024071008A1
(ja)
*
|
2022-09-26 |
2024-04-04 |
愛知県 |
抗原分子の単離方法
|
|
WO2024088987A1
(en)
|
2022-10-26 |
2024-05-02 |
F. Hoffmann-La Roche Ag |
Combination therapy for the treatment of cancer
|
|
AU2023411854A1
(en)
*
|
2022-12-19 |
2025-07-10 |
Harbour Biomed (Shanghai) Co., Ltd. |
“kappa/lambda” fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
|
|
EP4665385A2
(en)
|
2023-02-17 |
2025-12-24 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
TW202532440A
(zh)
|
2023-10-19 |
2025-08-16 |
美商建南德克公司 |
用於治療ＨＥＲ２陽性癌症的ＩＬ１５／ＩＬ１５Ｒα異二聚體ＦＣ融合蛋白及ＨＥＲ２ｘＣＤ３雙特異性抗體之組合
|